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Abstract
Aim:  To test the hypothesis that schizophrenia might be associated with alterations of the
endogenous cannabinoid system in human blood.
Results: Blood from 20 healthy volunteers and 12 patients with schizophrenia, 5 of which both
before and after a successful antipsychotic treatment, was analysed for: 1) the amounts of the
endocannabinoid anandamide; 2) the levels of cannabinoid CB1 and CB2 receptor mRNAs, and 3)
the levels of the mRNA encoding the enzyme fatty acid amide hydrolase (FAAH), responsible for
anandamide degradation.
The amounts of anandamide were significantly higher in the blood of patients with acute
schizophrenia than in healthy volunteers (7.79 ± 0.50 vs. 2.58 ± 0.28 pmol/ml). Clinical remission
was accompanied by a significant decrease of the levels of anandamide (3.88 ± 0.72 pmol/ml) and
of the mRNA transcripts for CB2 receptors and FAAH.
Conclusion: These findings indicate that endocannabinoid signalling might be altered during the
acute phase of schizophrenia not only in the central nervous system but also in the blood. These
changes might be related to the several immunological alterations described in schizophrenia.
Background
The Endogenous Cannabinoid (EC) system comprises at
least two cannabinoid receptors, the CB1 and CB2 recep-
tors, a series of lipophilic endogenous ligands, the endo-
cannabinoids (ECs), and enzymes for EC biosynthesis
and degradation [1]. Mounting evidence indicates that it
is involved in the physiological modulation of many cru-
cial functions in both the peripheral and the central nerv-
ous system [1]. It has been hypothesized that an alteration
of EC neurotransmission could play a role in neurologi-
cal, psychiatric and immunological disorders [2,3]. In this
context, it is possible that, along with other neurotrans-
mitter systems (i.e., dopaminergic, serotonergic), anoma-
lies of the ECs might take part in producing the clinical
picture of schizophrenia. This hypothesis relies on the fol-
lowing considerations:
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1) Subjects with acute cannabis intoxication often display
a schizophrenia-like syndrome, with hallucinations,
altered judgement, false beliefs, and cognitive impairment
[4]. In other, predisposed individuals, cannabis can pre-
cipitate a psychotic illness [5], although this does not nec-
essarily indicate a causative role of ECs in mental
disorders. Finally, lack of motivation, apathy and avoli-
tion are almost invariably observed in long-term cannabis
users, so as to mimic the picture of chronic or residual
schizophrenia.
2) Under physiological conditions, the EC system partici-
pates in the regulations of important functions, such as
rest, cognition, movement, memory, and perceptions [6].
Many of these functions are actually altered in the course
of schizophrenia.
3) There appears to be a substantial overlap between the
areas commonly believed to be involved in the pathogen-
esis of schizophrenia [7] and those expressing the highest
concentrations of EC receptors in the CNS [2], i.e. the lim-
bic system (hippocampus/amygdala), nigro-striatal areas,
and the prefrontal cortex, among the others.
There has been evidence in the recent literature [7–9] that
patients suffering from schizophrenia have detectable dif-
ferences in their EC signalling when compared to normal
controls. Leweke et al. [8] reported elevated levels of the
endogenous cannabinoid receptor ligand anandamide
[10] in the Cerebro-Spinal Fluid (CSF) of patients with
schizophrenia. Voruganti et al. [9] have shown a correla-
tion between the severity of psychotic symptoms and an
increase in cannabis-induced striatal dopaminergic neu-
rotransmission in a patient with the disorder. Finally, pol-
ymorphism of the gene encoding the CB1 receptor, which
is the cannabinoid receptor subtype mostly expressed in
the brain, has been associated with increased susceptibil-
ity to hebephrenic schizophrenia [11], thus suggesting
that a malfunctioning EC system could play a role in the
etiopathogenesis of this disorder.
There have been several reports that schizophrenia is
accompanied by overt alterations in the immune
response, as well as by changes in the function of immune
blood cells, and that many of these alterations can be nor-
malized by anti-psychotic drugs [[12–14] and [15] for
review]. In particular, a significantly increased number of
activated macrophages and lymphocytes has been
detected in the CSF of schizophrenic patients during acute
psychotic episodes [16,17]. Since activated macrophages
and lymphocytes release significant amounts of ECs [18–
20], it is possible that these blood cells contribute to some
extent to the previously observed elevated levels of anan-
damide in the CSF of patients with a diagnosis of schizo-
phrenia [8]. It is worthwhile noting that some of the
immune functions previously found to be altered during
acute schizophrenia, such as interleukin and tumor necro-
sis factor-α release, are also known to be influenced by
ECs acting at both CB1 and, particularly, CB2 cannabinoid
receptors in macrophages, lymphocytes and dendritic
cells [3]. Notwithstanding the above observations, and
despite the fact that ECs can easily cross the blood brain
barrier [10], the levels of these compounds in the blood of
schizophrenic patients have never been assessed.
Aims of the study
We analysed the peripheral blood of patients and normal
controls, in order to detect any differences in the levels of:
(i) the endogenous ligands of cannabinoid receptors (the
endocannabinoids, [10]); (ii) the cannabinoid CB1 and
CB2 receptors, and (iii) the fatty acid amide hydrolase
(FAAH), one of the enzymes mostly involved in endocan-
nabinoid inactivation [21].
We report that anandamide plasma levels are elevated in
untreated patients with schizophrenia, and that the
amounts of this compound as well as of CB2 receptors and
FAAH are decreased after a successful pharmacological
treatment.
Results
Psychiatric evaluation
Table 1 displays the data related to the BPRS total score for
all the patients included in the study. In addition, the
patients in subgroup 1 have been rated as ranging from
moderately ill to severely ill (CGI score from 4 to 6). All
patients who were reassessed showed a statistically signif-
icant difference between the pre- and post-treatment
scores at the BPRS and CGI, which dropped by more than
50% in all 5 cases considered (Table 1). Patients 3, 5 and
8 in subgroup 2 scored 1 (much improved), whereas
patients 6 and 7 in the same subgroup were evaluated as
moderately improved (CGI score = 2).
Anandamide, cannabinoid receptor and FAAH blood levels
Table 1 also shows the blood levels of anandamide in
each of the twelve patients affected by schizophrenia. The
mean ± SEM amounts of anandamide levels in the control
volunteers and the patients with acute schizophrenia are
also shown in Table 1 and in its legend. A statistically sig-
nificant difference between the two groups was found,
whereas the mean values for the patients in remission
were not significantly different from those of the control
subjects.
Clinical improvement, with the reduction in the BPRS and
CGI scores, was paralleled by the decrease in both the lev-
els of peripheral ANA (assessed in those 5 patients sam-
pled before and after pharmacological treatment, Table 1,
Fig. 1) and of the intensity of the bands for the mRNALipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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transcripts of FAAH and CB2 (assessed in those 5 patients
sampled before and after pharmacological treatment, Fig.
2). We did not observe any consistent difference for the
CB1 mRNA transcript, which appeared to be less expressed
than that of CB2 in all the blood samples analysed (Fig.
2b).
Discussion
Despite several suggestions that the EC system may play a
role in the pathogenesis of schizophrenia [7,9,22], and
the finding of elevated levels of anandamide in the CSF of
patients suffering from schizophrenia [8], no study has
addressed so far the question of whether the EC system is
also altered in the serum and mononucleated cells from
the blood of patients with this mental disorder. This issue
is important in view of the several immunological corre-
lates of schizophrenia, which include, among others, a
shift from a Th-1-type to a Th-2-type immune response, a
significant increase of activity of blood monocytes/macro-
phages, and a corresponding up-regulation of cytokine
release [15]. Indeed, the ECs have a well-established
immune-modulatory effect [23,24,20]. Thus, possible
changes in the blood levels of these endogenous media-
tors could explain in part, or be a consequence of, the
modified immune response observed in the course of
schizophrenia. Furthermore, since the strong impact of
acute schizophrenia on some immune functions can be
attenuated by treatment with anti-psychotic drugs
[15,25], the effect of antipsychotic medications on the
Table 1: BPRS and CGI scores and anandamide blood levels of the twelve patients with schizophrenia included in this study. 
Patient Number Anandamide levels in the blood during 
the acute phase of schizophrenic illness 
(pmol/ml)
Anandamide levels in the blood during 
remission of schizophrenic illness 
(pmol/ml)
BPRS (and CGI) Scores 
Acute Remission
1 11.7 59 (5)
2 7.3 64 (5)
3 8.4 4.4 68 (6) 25 (1)
4 8.2 48 (4)
5 6.3 6.2 60 (5) 20 (1)
6 5.3 2.2 66 (6) 29 (2)
7 7.7 4.1 56 (5) 26 (1)
8 6.7 2.5 70 (6) 29 (2)
9 7.5 55 (4)
10 9.7 57 (4)
11 8.7 56 (4)
12 6.0 52 (5)
7.79 ± 0.50
(P = 4.5 × 10-8 vs. Control)
3.88 ± 0.72
(P = 0.16 vs. Control)
Five of these patients were assessed before and after remission of the symptoms (indicated by the significant decrease in the global BPRS and CGI 
scores) induced by treatment with olanzapine. CGI score ranged from 6 (severely affected) to 1 (much improved), and are shown in parentheses. 
The amount of anandamide in healthy volunteers (control) was 2.58 ± 0.28 pmol/ml (mean ± SEM, n = 20). Means were compared to the control by 
the unpaired Student's t test, threshold of significance was 0.95.
Amounts of anandamide (pmol/ml) in the blood of the 5  patients with schizophrenia before and after pharmacological  treatment Figure 1
Amounts of anandamide (pmol/ml) in the blood of the 5 
patients with schizophrenia before and after pharmacological 
treatment. *, P < 0.02 by the paired Student's t test.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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possible modifications of the EC system in the blood of
these patients also needs to be assessed.
Our study suggests the existence of a significant alteration
in the peripheral blood levels of schizophrenic patients of
both the endocannabinoid anandamide and the mRNA
for the anandamide degrading enzyme, FAAH. Further-
more, we found that the elevation of anandamide levels in
our sample is confined to the acute phases of disease, to
then normalize after a successful pharmacological treat-
ment. Eventually, there were no statistically significant
differences in anandamide levels between treated patients
and controls. However, no direct correlation between
anandamide blood levels and the BPRS or CGI scores of
each patient, be it before or after remission, was found.
Our results suggest that an acute psychotic episode might
be characterised, among other factors, by an elevation in
the peripheral concentration of anandamide, thus possi-
bly inducing a compensatory increased expression of the
degrading enzyme, FAAH, in an attempt to normalise
their circulating levels. It is of interest that our patients
consistently showed the same pattern, with their level of
circulating anandamide forming two well-identifiable
and distinct clusters at around 8 and 3 pmol/ml for group
1 and 2, respectively. Anti-psychotic medications seem to
have played a crucial role in these patients by thwarting
clinical symptoms on the one hand, and, in parallel, by
reducing the levels of endocannabinoids and FAAH
mRNA on the other hand. We did not identify any
patients failing to respond to their pharmacological treat-
ment, although it would have been interesting to measure
the concentration of anandamide in the absence of an
improved clinical presentation. This event would have
carried important information as to whether decreased EC
concentration was related to clinical amelioration or
rather to pharmacological treatment per se, regardless of
clinical outcome.
The peripheral elevation of anandamide levels might be
related to the hypothesized anomaly of this signalling sys-
tem in the brain of patients with schizophrenia, since
these compounds can easily cross the blood brain barrier
[10]. However, it is unlikely that changes in the peripheral
amounts of ECs found in the blood can reflect to a great
extent alterations occurring at the CNS level, in schizo-
phrenia as well as other neurological and psychiatric dis-
Expression levels of CB1, CB2 and FAAH mRNAs in patients in acute phase of schizophrenic illness and following pharmacolog- ically-induced remission of the symptoms Figure 2
Expression levels of CB1, CB2 and FAAH mRNAs in patients in acute phase of schizophrenic illness and following pharmacolog-
ically-induced remission of the symptoms. The expression levels were evaluated by RT-PCR as described in the methods. Lanes 
1, 3, 5, 7, 9: patients n° 3, 6, 8, 5 and 7 (see Table 1), in acute phase; lanes 2, 4, 6, 8 and 10: patients n° 3, 6, 8, 5 and 7, in remis-
sion. Panel A, B, C and D are relative to PCR analysis for β2-microglobulin (house-keeping), CB1, CB2 and FAAH, respectively. 
The bands shown in the figure are from 20 (Panel A), 35 (Panel B), 30 (Panel C) and 30 (Panel D) PCR amplification cycles.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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orders, since these compounds: (i) due to their
lipophilicity act as autocrine/paracrine mediators, and no
blood EC carrier protein has been identified to date; and
(ii) are also produced by blood cells. More probably, the
changes in anandamide blood levels found here might be
a consequence, or alternatively one of the causative fac-
tors, of the previously observed immunological abnor-
malities in patients with schizophrenia [15]. For example,
in view of the negative effect of leptin on endocannabi-
noid biosynthesis [26], and of the reduced levels of this
hormone during acute schizophrenia [27], it is possible
that reduced leptin causes the increased levels of blood
anandamide observed in the schizophrenic patients inves-
tigated in the present study. This hypothetical mechanism
would explain also why olanzapine was found here to
lower EC levels back to those observed in healthy volun-
teers, since treatment of schizophrenia with this antipsy-
chotic drug was shown previously to restore normal
serum leptin levels [28]. Alternatively, since antipsychot-
ics are also known to reduce the number and/or activity of
leukocytes [15], it is possible that the reduced levels of
anandamide following olanzapine treatment are a mere
consequence of the reduced activity of lymphocytes and
monocytes, which are normally capable of producing
anandamide only after activation [19,20,29].
Regarding the reduction, also observed here, of cannabi-
noid CB2 receptor mRNA following treatment with olan-
zapine, again this could be a consequence of reduced
activity of blood leukocytes, since also CB2 expression has
been previously shown to be subject to regulation in acti-
vated macrophages and leukocytes [3]. Interestingly, also
the function of G-proteins in the blood has been recently
shown to be down-regulated after treatment with neu-
roleptic drugs [30,31], and since CB2 is a G-protein-cou-
pled receptor [1,10], it is likely that the reduction of the
expression of this receptor detected after treatment with
olanzapine and subsequent recovery from the symptoms
of schizophrenia is also accompanied by a corresponding
decrease of CB2 receptor functionality.
Clearly, blood endocannabinoids cannot be regarded yet
as possible markers of acute psychotic disorders, and even
less as predictors of the patients' response to antipsychotic
medication. Furthermore, we did not test the specificity of
ECs alterations to schizophrenia, and it may be that other
major psychoses exhibit similar biochemical aberrations,
and perhaps similar stage-related fluctuations. Therefore,
our data warrant further investigations with the aim of
better understanding the pathological relevance of this as
well as of other correlative studies.
Conclusions
The present study carries the following interesting and
potentially important implications:
1) It lends further support to the hypothesis of an involve-
ment of the EC system in schizophrenia, clearly demon-
strating an anomaly in three separate components of this
system, anomaly that, at least in our sample, appears to be
associated with an acute phase of the illness. However, the
small size of our sample warrants for great caution when
interpreting these results.
2) It suggests that at least part of the immunological
abnormalities observed during acute schizophrenia might
correlate with changes in the "output" of the EC system in
the blood.
Methods
Study design, subjects and psychiatric assessment and 
treatment
A case-control study design was used. Subjects were
selected from patients treated in the clinical facilities of
the Department of Mental Health in Pomigliano, Naples,
Italy, from January to December 2001. Patients were
selected only if showing, or described in the medical
records as affected by, symptoms of schizophrenia, and if
wishing to take part in the study. After this first step, the
recruited subjects received a diagnostic assessment, and
only those meeting the DSM-IV criteria for schizophrenia
[32] entered the study. Other necessary criteria for inclu-
sion were: absence of previous or present neurological dis-
orders, no abuse of cannabis in the year preceding the
study, and absence of a significant learning disability
(IQ<85). All the patients included had to be in a quite
controlled setting (namely, their family environment),
where no abuse of cannabis and compliance to treatment
could be assessed with a high degree of certainty. These
strict criteria carried inevitable reflections on the number
of patients included in the study.
The individuals in our research (n = 12) were split in two
subgroups. In subgroup 1 were those in an acute phase of
their schizophrenic illness, who had not received pharma-
cological treatment for at least 30 days prior to evaluation,
9 males and 3 females, with a mean age of 32.9 ± 7.0 years
(range, 18–45 years), of Caucasian race (n = 12). All indi-
viduals received the Diagnostic Interview for Genetic
Studies (DIGS; [33]), a semi-structured DSM IV interview.
All patients were rated also by means of the Clinical Glo-
bal Impression scale (CGI; [34]), and the treatment out-
come was evaluated with the CGI-Improvement (CGI-I).
We used the Brief Psychiatric Rating Scale (BPRS; 18-item
version; [35]) to characterize the severity of the symptoms
of the illness, where 1 indicates absent and 7 severe.
The second subgroup (n = 5) consisted of patients previ-
ously assigned to subgroup 1, who had achieved clinical
remission since at a least one month, following a success-
ful pharmacological treatment with olanzapine (patientsLipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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3 and 5 were on 20 mg/day, whereas subjects 6, 7 and 8
received 25 mg/day). The re-test procedure for the 5
probands was performed 92 ± 11 days after the assess-
ment in the acute phase of the illness. Clinical remission
was defined a priori as at least 50% reduction on the BPRS
score and a clinical evaluation of 1 (much improved) or 2
(moderately improved) at the CGI-I score. In particular,
patient Nr. 3 was investigated during the third episode of
her disease. She had been treated with risperidone at the
onset. We switched to olanzapine because of hyperprol-
actinemia. Her response to treatment was satisfactory with
both medications, and she always achieved a nearly com-
plete remission. Relapses were apparently caused by an
excessive reduction or a spontaneous discontinuation of
her medication regime. Patient Nr. 5 was suffering from
the second episode of schizophrenia. We treated her with
risperidone (first episode) and then olanzapine for the
episode described here. The relapse was caused by her
arbitrarily stopping her medication. Patient Nr. 6 was at
his first episode of schizophrenia, which however had
lasted for a prolonged time because it went untreated
(more than a year). In fact, his family postponed his refer-
ral to mental health facilities because of fear of stigmatiza-
tion. We started him on olanzapine 20 mg/day, but he
needed 25 mg to show a satisfactory response (CGI from
6 to 2). Patient Nr. 7 was experiencing several positive
symptoms since two years, with serious consequences
such as loss of his job. His schizophrenia did not respond
to two classical antipsychotics administered by a previous
psychiatrist. The initial 20 mg of olanzapine had to be
titrated up to 25 to obtain the optimal response. Finally,
patient Nr. 8 was treated with olanzapine since he was
included in the study. He had previously not agreed to be
treated, and had been suffering from several positive
symptoms for approximately seven years. He only had
occasional administrations of haloperidol, which was
added to his food by the patient's wife without him being
aware of that. In retrospect, there appeared to be no
response because of these treatment inconsistencies.
Twenty normal controls were recruited from the medical
and nursing staff at the Department of Mental Health in
Pomigliano. They were in the same age range as the study
patients, and were likewise comparable for level of educa-
tion and gender representation. A normal IQ, absence of
previous and present neurological disorders, and having
not abused marijuana/exogenous cannabinoids were
used as inclusion criteria for controls. The control subjects
had no first-degree relative suffering from a major psychi-
atric disorder.
All subjects gave 10 ml blood for the laboratory testing.
All blood samples were taken in the morning, from non-
fasting subjects, and there were no feeding-related varia-
bles that could account for any possible difference in ECs
levels between groups.
Biochemical analyses
Lipid Extraction
Peripheral blood samples (10 ml) were collected by vein
suction in EDTA (25 mM final concentration) and proc-
essed no later than 3 hours after blood was drawn. For the
LC-MS determinations, EDTA and phenyl-methyl-sulfo-
nyl-fluoride (PMSF) (100 µM final concentration) were
added to blood samples. PMSF is an inhibitor of fatty acid
amide hydrolase (FAAH), and was added in order to pre-
vent endocannabinoid degradation. Five ml of whole
blood for each sample was carefully layered over 5 ml of
HISTOPAQUE® 1077 solution (SIGMA) in ACCUSPIN®
tubes (SIGMA) and centrifuged at 400 × g for 30 min at
room temperature. After centrifugation, erythrocytes and
granulocytes sedimented at the bottom of the tube. After
removal of the clear plasma layer from the top of the tube,
the opaque layer (about 2 ml) containing the mononu-
clear cells was collected, resuspended by gentle aspiration
in 10 ml of phosphate buffered saline (PBS) and centri-
fuged at 250 × g for 10 min at room temperature. The cell
pellet was resuspended, washed twice in 5 ml of PBS and
stored at -80°C for RNA extraction. For quantitative deter-
minations, the plasma and the mononucleate cell layers
were collected together, the proteins precipitated by add-
ing 3 vol. of acetone, the supernatants were collected and
subjected to lipid extraction with methanol/chloroform.
Enough of each solvent was added to reach a final ratio
buffer/methanol/chloroform of 1:1:2 (v/v/v). Methanol
containing 5 pmol of d8-anandamide was added as
internal standard. The organic phase was then dried under
nitrogen and purified by means of open bed chromatog-
raphy on silica gel [36,37].
Liquid chromatography-Atmospheric pressure chemical ionization-
mass spectrometry (LC-APCI-MS) quantification of anandamide 
levels
The lipid extracts were analyzed by liquid chromatogra-
phy-atmospheric pressure chemical ionization-mass spec-
trometry (LC-APCI-MS) by using a Shimadzu HPLC
apparatus (LC-10ADVP) coupled to a Shimadzu (LCMS-
2010) quadrupole MS via a Shimadzu APCI interface. MS
analyses were carried out either in the selected ion moni-
toring (SIM) mode as described previously [26]. The tem-
perature of the APCI source was 400°C, the HPLC column
was a Phenomenex (5 µm, 150 × 4.5 mm) reverse phase
column, eluted as described [37]. Anandamide (retention
time 14.5 min) was quantified by isotope dilution with
the above-mentioned deuterated standards (same reten-
tion time and m/z = 356.3) and its amounts in pmoles
normalized per ml of processed blood. Intra-assay varia-
tion using this method was 2.5 ± 0.3%, whereas inter-
assay variation was 10.1 ± 2.5% (means ± SEM, n = 4).Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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RNA extraction and semi-quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) analyses
Total RNA was extracted from mononuclear cells by Tri-
zol® reagent (Life Technologies) according to the manu-
facturer's intructions. To remove contaminant DNA, 4 µg
of RNA samples were DNAse-digested utilizing the DNA-
free® (Ambion) protocol. 2 µg of total RNA were reverse
transcribed in a 20 µl reaction mixture containing: 75 mM
KCl, 3 mM MgCl2, 10 mM dithiothreitol, 1 mM dNTPs, 50
mM Tris-HCl pH 8.3, 20 units of RNAse inhibitor
(Roche), 0.125 A260  units of hexanucleotide mixture
(Roche) for random-priming and 200 units of reverse
transcriptase (Superscript®, GIBCO). The reaction mixture
was incubated at room temperature for 10 minutes and at
42°C for 90 min, then the reaction was stopped by heat-
ing at 95°C for 5 min, cooled on ice, and stored to -20°C.
Control samples (no-RT) were prepared by omitting
reverse transcriptase in the retrotrascription mixture. DNA
amplification was performed in a 50 µl PCR reaction mix-
ture containing: 0.5–2 µl of the retro-trascription mixture,
1X PCR buffer (supplied as component of the DNA
polymerase kit), 2 mM MgCl2, 250 µM dNTPs, 0.5 µM
each of 5' and 3' primers and 2.5 units of Platinum®Taq
DNA polymerase (Life Technologies). The mixtures were
amplified in a PE Gene Amp PCR System 2400 thermocy-
cler (Perkin Elmer). The primers used were: CB1 sense
primer, 5'-CAG AAG AGC ATC ATC CAC ACG TCT G-3';
CB1 antisense primer 5'-ATG CTG TTA TCC AGA GGC
TGC GCA GTG C-3'; CB2 sense primer 5'-TTT CCC ACT
GAT CCC CAA TG-3'; CB2 antisense primer 5'-AGT TGA
TGA GGC ACA GCA TG-3'; FAAH sense primer 5'-GCC
TGG GAA GTG AAC AAA GGG ACC-3'; FAAH antisense
primer 5'-CCA CTA CGC TGT CGC ACT CCG CCG-3'; β2-
microglobulin sense primer 5'-CCA GCA GAG AAT GGA
AAG TC-3'; β2-microglobulin antisense primer 5'-GAT
GCT GCT TAC ATG TCT CG-3'.). The amplification profile
consisted of an initial denaturation of 2 min at 95°C and
20–35 cycles of 30 sec at 95°C, annealing for 30 sec at
55°C (β2-microglobulin) or at 60°C (CB1, CB2  and
FAAH) and elongation for 1 min at 72°C. A final
extension of 10 min was carried out at 72°C. The expected
sizes of the amplicons were 338 bp for CB1; 329 bp for
CB2; 202 for FAAH and 269 bp for β2-microglobulin. The
β2-microglobulin house-keeping gene expression was
used to evaluate variations in the quality and content of
the mRNA and to monitor cDNA synthesis in the different
preparations. Furthermore the PCR primers for β2-
microglobulin and FAAH were selected on the basis of the
sequence of the β2-microglobulin gene (NCBI accession
number M17987) by including the intron 402–1017, and
of the sequence of the FAAH human gene (NCBI accession
number AF098012) by including the intron 497–722. In
the presence of contaminant genomic DNA, the expected
size of the amplicon would be 426 and 885 bp for FAAH
and  β2-microglobulin, respectively. 10–20 µl of PCR
products were electrophoresed on 2% agarose gel (MS
agarose, Roche) in TAE buffer at 4 V/cm for 4 h. Ethidium
bromide (0.1 µg/ml) was included both in the gel and
electrophoresis buffer and PCR products were detected by
UV visualization and recorded by photo (Polapan 55,
Polaroid). Evaluation of the relative expression levels was
performed by analysing the amount of amplicon synthe-
sized at different numbers of amplification cycles for a
fixed quantity of cDNA in the assay. In order to obtain a
quantitative evaluation of the relative amounts of the
mRNA transcripts, the different PCR reactions were per-
Table 2: Brief Psychiatric Rating (BPRS) Scale. Score for all the 18 items of the Brief Psychiatric Rating (BPRS) for each of the twelve 
patients with schizophrenia included in this study
N °  P a t i e n t 123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8
1 434226114355336421
2 356336114266335322
3  a c u t e 564337213175426216
3  r e m i s s i o n 222121112111211211
4 243225212264225211
5  a c u t e 262217112266227212
5  r e m i s s i o n 121111112111111111
6  a c u t e 355225413156646511
6  r e m i s s i o n 223112212121221211
7  a c u t e 235245114134436611
7  r e m i s s i o n 122121113111212211
8  a c u t e 455336212667447311
8  r e m i s s i o n 331132113111211211
9 243235213355335321
1 0 244525113355335411
1 1 444415213345235411
1 2 144615131245126222Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/5
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formed with a different number of cycles. Differences in
band intensities obtained using a non-saturating number
of cycles, in relation to the intensity of the housekeeping
mRNA transcript (i.e. β2-microglobulin, which works as
an "internal standard"), are highly indicative of differ-
ences in the levels of expression of the corresponding
genes.
Statistical analyses
Results of the anandamide level measurements, expressed
in pmol/ml of blood and as means ± SEM, were compared
by the unpaired Student's t test. When data from patients
before and after pharmacological treatment were com-
pared, the paired Student's t test was used.
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